Loading
Alzheimer Disease (AD) / Ischemic Stroke / Cerebrospinal Fluid Flow Cytometry · Observational Study
ClinicalTrials.gov · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a completed prospective observational study examining associations between cerebrospinal fluid mitochondrial biomarkers (measured by flow cytometry) and functional outcomes in ischemic stroke patients, with Alzheimer disease patients as disease controls. No results are posted in this registry record, so the direction, magnitude, and statistical significance of any findings cannot be assessed.
Observational. Ischemic Stroke, Alzheimer Disease (AD); age from 18 Years. Intervention: Ischemic Stroke Cohort; Alzheimer Disease Control Cohort. Compared with: Alzheimer disease patients as disease controls for biomarker comparison.. n = 40. 1 site: China.
This is a completed prospective observational study examining associations between cerebrospinal fluid mitochondrial biomarkers (measured by flow cytometry) and functional outcomes in ischemic stroke patients, with Alzheimer disease patients as disease controls. No results are posted in this registry record, so the direction, magnitude, and statistical significance of any findings cannot be assessed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is a completed observational study with no posted results, examining associations between cerebrospinal fluid mitochondrial biomarkers and stroke outcomes using a small sample and surrogate biomarker measurements rather than hard clinical endpoints.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07600996). This is a study registration, not published results. Lead sponsor: Capital Medical University. Recruitment status: COMPLETED. Study type: OBSERVATIONAL. Enrollment: 40 participants (ACTUAL). Conditions: Ischemic Stroke, Alzheimer Disease (AD). Interventions: DIAGNOSTIC_TEST: Cerebrospinal Fluid Flow Cytometry. Primary outcome measures: Association Between Cerebrospinal Fluid MitoTracker-Positive Event Count and 90-Day Modified Rankin Scale Score in Patients With Ischemic Stroke , Day 90 after stroke onset. Brief summary: This prospective observational study aims to investigate cerebrospinal fluid mitochondrial biomarkers in patients with ischemic stroke and Alzheimer disease controls who undergo diagnostic lumbar puncture for clinical indications at Xuanwu Hospital, Capital Medical University. Residual cerebrospinal fluid samples will be analyzed by flow cytometry to quantify mitochondrial content, mitochondrial membrane potential, and cellular or vesicular source-related markers. The flow cytometry panel will include MitoTracker, JC-1, and membrane-associated markers including CD45, CD41, CD24, vWF, and EAAT1. In patients with ischemic stroke, the study will further examine whether cerebrospinal fluid mitochondrial measurements are associated with neurological severity and functional outcomes, including admission and discharge NIHSS scores and the 90-day modified Rankin Scale score. Alzheimer disease patients undergoing diagnostic lumbar puncture will serve as disease controls for biomarker comparison.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.